Enveric Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ENVERIC BIOSCIENCES, INC. | ||
| March 25, 2024 | By: | /s/ Dr. Joseph Tucker |
|---|---|---|
| Dr. Joseph Tucker | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| March 25, 2024 | By: | /s/ Dr. Joseph Tucker |
|---|---|---|
| Dr. Joseph Tucker | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| March 25, 2024 | By: | /s/ Kevin Coveney |
| Kevin Coveney | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
| March 25, 2024 | By: | /s/ Michael Webb |
| Michael Webb | ||
| Director | ||
| March 25, 2024 | By: | /s/ George Kegler |
| George Kegler | ||
| Director | ||
| March 25, 2024 | By: | /s/ Marcus Schabacker |
| Marcus Schabacker | ||
| Director | ||
| March 25, 2024 | By: | /s/ Frank Pasqualone |
| Frank Pasqualone | ||
| Director | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.